Over two years ago, four new antiretrovirals were approved: Two of these introduced new classes of therapy, and two others provided new hope for already resistant viruses. These were added to the 20 existing antiretrovirals and have provided even more potent combinations that confer less resistance and long-term toxicities. In spite of these potent, cleaner regimens, resistance and intolerance are inevitable in some cases. Thus, there is a need for both new classes of antiretrovirals and enhancement of existing classes. There are over 50 new compounds in many different phases of development. This article will focus on medications currently in Phase II and III development.

Integrase Inhibitors
Integrase Inhibitors block the activity of the integrase enzyme, which is responsible for viral insertion into the DNA of the CD4+ cell. One such Integrase Inhibitor is Elvitegravir, Gilead’s competitor to Isentress (raltegravir, Merck). However, elvitegravir may be dosed once daily when combined with a pharmacokinetic (PK) enhancer (i.e. ritonavir or cobicistat). Elvitegravir is one component of Gilead’s “Quad,” a 4-in-1 coformulation of elvitegravir, GS-9350 (cobicistat) and emtricitabine/tenofovir (Truvada). Phase II studies saw the Quad regimen meet the primary endpoint of non-inferiority in head-to-head trials versus Atripla (efavirenz/emtricitabine/tenofovir). Phase III trials are underway as of April 2010, with the “Quad” regimen going head-to-head against Reyataz (efavirenz and ritonavir-boosted atazanavir) in treatment-naive individuals.1

Another Integrase Inhibitor currently in Phase II trials is S/GSK1349572 (Viiv, Shlongi), which showed a significant viral load reduction over a ten day phase IIa dosing trial even in the absence of a PK enhancer. Resistance data showed this compound maintains activity despite integrase cross-resistance, which does not hold true for elvitegravir. Phase IIb trials are underway, with Phase III trials to commence in late 2010.2

Pharmacokinetic Enhancer
Ritonavir (Norvir) is the only ‘booster’ approved by the Food and Drug Administration used to increase levels of antiretrovirals, most particularly protease inhibitors. While boosting is indicated in treatment-experienced patients, ritonavir carries side effects which make it intolerable in patients, such as gastrointestinal intolerance and lipid elevations. Cobicistat (GS-9350) is a ‘pharmacoenhancer’ that possesses no antiretroviral activity. It increases drug levels through inhibition of Cytochrome P4503A —the same mechanism as ritonavir. Phase II trials comparing cobicistat and ritonavir saw similar gains in CD4+ cell counts and decreases in viral load in their respective arms. Side effects were comparable, albeit less frequent, in the cobicistat arm. Phase III trials will commence later this year, comparing cobicistat versus ritonavir with various combinations. One point of concern in the cobicistat arm was a decrease in estimated glomerular filtration rate (GFR), through a false elevation in serum creatinine. Fortunately, this does not occur via the same pathway as most other nephrotoxic drugs. Further investigation is warranted to better understand the mechanism by which this occurs.1

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Currently, the NNRTI preferred by the Department of Health and Human Services is efavirenz. NNRTIs work to prevent DNA synthesis of the retrovirus through structural alteration of the Reverse Transcriptase enzyme. When resistance is an issue, most NNRTIs are rendered inactive with the exception of etravirine ilpivirine (TMC 278, Tibotec), a second generation NNRTI which demonstrates antiretroviral activity in the presence of the K103N mutation—the signature efavirenz mutation. Rilpivirine demonstrated virologic efficacy comparable to efavirenz at week 48 (76.9% v. 80%) and sustained efficacy at week 96. The most commonly reported moderate to severe adverse events possibly related to study medication (e.g. nausea, dizziness, abnormal dreams, rash, somnolence and vertigo) occurred less frequently with rilpivirine than with efavirenz. Overall, rilpivirine demonstrates efficacy similar to efavirenz with a lesser incidence of neurological and psychiatric effects. Current Phase III trials are underway to replicate bioequivalence in the coformulation of rilpivirine.
and emtricitabine/tenofovir. If approved, rilpivirine will be utilized as part of a first-line regimen—unlike its Tibotec counterpart, etravirine, which is not indicated as such.3

Other NNRTIs in Phase II development include GSK2248761 (ViiV) and RDEA806 (Ardea). Both possess anti-retroviral activity despite efavirenz resistance.

**CCR5 Antagonists**

Presently, maraviroc is the only FDA-approved CCR5 antagonist available. Maraviroc blocks the CCR5 coreceptor which HIV uses to bind and enter a human macrophage. It recently received indication for treatment in naive individuals and serves as an additional option in the presence of certain viral strains when other classes are not an option.4 Vicriviroc (Merck/Schering-Plough) is another CCR5 Inhibitor currently in Phase II/III trials. However, it has experienced obstacles. The first Phase II trials failed to establish an adequate dose. As of May 2008, two phase III trials (VICTOR-E3 and VICTOR E4) in treatment-experienced patients were initiated. Late stage clinical trials did not meet primary efficacy endpoints and Merck decided not to seek approval for the drug in treatment-experienced patients. However, trials in treatment-naïve individuals will resume.5,6,7 Like maraviroc, multiple drug interactions with other antiretrovirals exist and side effects, such as increased risk of respiratory infection, may occur.8

**Nucleoside Reverse Transcriptase Inhibitors (NRTIs)**

NRTIs are considered the backbone of antiretroviral therapy. Unlike their NNRTI counterparts, NRTIs structurally resemble compounds used in viral DNA chain elongation, essentially tricking the virus into incorporating these analogues and terminating the growing chain. First-line combination(s) usually consist of lamivudine (Epivir) or emtricitabine (Emtriva) and another nucleoside, such as tenofovir or abacavir (Ziagen). While the regimens are highly potent, resistance to lamivudine and emtricitabine occurs quite frequently. Among the other nucleosides, multi-drug resistance or long-term morphological changes warrant the need for newer agents.

Amdoxovir (DAPD, RFS Pharmaceuticals) is currently in Phase II trials. Although it demonstrates activity against the main lamivudine/emtricitabine mutation, M184V, amadoxovir must be taken twice daily. In addition, visual problems may occur, but resolve upon discontinuation.9

Elvucitabine (ACH-126, Achillon) is virologically equivalent to lamivudine (3TC) when combined with efavirenz and tenofovir as a first-line regimen taken for 96 weeks. However, because of the small size of this phase II trial, and the high dropout rate, elvucitabine lagged 3TC from a statistical standpoint. Further research is needed to see where elvucitabine fits in treatment. Like lamivudine and tenofovir, elvucitabine also possess anti-Hepatitis B activity.10

**Maturation Inhibitors**

Maturation inhibitors, in later stages of viral replication, interfere with protease processing of a newly translated HIV polyprotein precursor called gag. This molecule contains a number of HIV proteins in a single polypeptide, which is then cleaved by an enzyme, called protease, to produce functional structural proteins. However, unlike the protease inhibitors, bevirimat binds to the gag protein, not protease. Two agents currently in Phase II trials include Bevirimat (PA457, MPC-4326, Myriad) and Vivecon (MPC-9055). While these agents offer a new opportunity, the potential for cross-resistance amongst previous protease inhibitor use is possible. Thus, baseline resistance testing may be warranted.

**Monoclonal Antibodies**

Similar to CCR5 antagonists, these compounds use monoclonal—that is, all identical—antibodies, rather than a drug molecule, to block the CCR5 co-receptor. PRO140 (Progenics) is currently in Phase II trials and has shown promise in terms of potency and duration of action. It is administered via subcutaneous injection, yet only requires dosing every other week, which may provide an option for patients where adherence may be an issue. PRO140 is generally well-tolerated, with injection site reactions (e.g. swelling, irritation, and pain) being the major side effects.10 In addition, Phase II studies of ibilazumab (TNX-355, Genetech) are scheduled to end by late 2010.11-13 Both compounds were granted fast-track status by the FDA, and may provide “salvage” in patients with a highly resistant virus, much like enfuvirtide (Fuzeon) did in 2003.

Michael Modzelewski is an AAHIVM certified pharmacist and has practiced in the New York City community for over 5 years, with a emphasis on specialized HIV care.

**Anal Cancer Increasing among People Living with HIV**

*By Timothy Wilkin, MD, MPH*

**Why Screen for Anal Cancer in HIV-Positive Patients?**

Anal cancer is emerging as a common non-AIDS defining cancer in HIV-positive people. Anal cancer, like cervical cancer, is caused by infection with high-risk types of human papillomavirus (HPV). Anal cancer is also sometimes associated with HIV treatment. For example, the protease inhibitor saquinavir (Invirase, Fortovase) is associated with a higher risk of developing anal cancer. Anal cancer is a common non-AIDS defining cancer and is associated with several factors.

Anal cancer is emerging as a common non-AIDS defining cancer in HIV-positive people. Anal cancer, like cervical cancer, is caused by infection with high-risk types of human papillomavirus (HPV). Anal cancer is also sometimes associated with HIV treatment. For example, the protease inhibitor saquinavir (Invirase, Fortovase) is associated with a higher risk of developing anal cancer. Anal cancer is a common non-AIDS defining cancer and is associated with several factors.
papillomavirus (HPV)—low-risk types of the virus can cause genital and anal warts. The rate of anal cancer appears to be increasing in the era of antiretroviral therapy. A recent analysis from Kaiser-Permanente in California estimated the rate of anal cancer among the HIV-positive population to be 174/100,000 person-years—and even higher among individuals with lower CD4+ counts—compared to 2/100,000 person-years among the HIV-negative population. This rate is significantly higher than the rate of cervical cancer before Papanicolaou (PAP) screenings became routinely performed on women (35/100,000).

Anal Cancer: Who to Screen
HIV-positive men with a history of sex with other men appear to be at highest risk for anal cancer. A study conducted by the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) combined data from 19 cohorts of HIV-positive participants and estimated the cumulative incidence of anal cancer by age 60 years to be 2.8%. Less is known about the rate of anal cancer in HIV-positive women or in men without a history of sex with other men. However, anal HPV infections are more common than cervical HPV infections among HIV-positive women. About 10% of HIV-positive women have pre-cancer of the anus. The rate of anal cancer is seven times higher for HIV-positive women compared with HIV-negative women.

Organizations setting the standard for healthcare maintenance of HIV-infected patients have not yet adopted recommendations for routine anal cancer screening. However, the New York State AIDS Institute recommends anal cancer screening for HIV-positive men with a history of sex with other men, HIV-positive women with a history of pre-cancer of the cervix or vulva, and anyone with a history of anal or genital warts.

Anal Cancer: How to Screen
The screening protocol to prevent anal cancer is based on that for cervical cancer. The goal of screening is to prevent invasive anal cancer by identifying and removing pre-cancerous areas of the anal skin, called high-grade anal intraepithelial neoplasia (HGAIN), before they progress to invasive cancer. The initial screening test is a PAP smear of the anus. The skin around the anus should also be examined for warts or dark patches. Patients with an abnormal PAP smear or an abnormal exam should be referred for anoscopy.

Anoscopy
High resolution anoscopy is done to identify HGAIN or warts. A lubricated plastic anoscope is inserted into the anus. A cotton swab wrapped in gauze and soaked in diluted vinegar is then inserted through the anoscope, and the anoscope is removed, leaving the gauze in place. The acetic acid reacts with the skin, making HGAIN appear white. After two minutes, the gauze is removed and the anoscope re-inserted. A colposcope (a machine used to look at the skin under magnification) is used to view the walls of the anus under magnification to look for areas of whitening consistent with HGAIN. Areas suspicious for pre-cancer are biopsied. If HGAIN is found on these biopsies, then the patient is seen for treatment of these areas.

Treatments of HGAIN
The Food and Drug Administration (FDA) has approved the infrared coagulator (IRC), a medical device that delivers controlled pulses of visible and infrared light through an applicator that is applied directly to the skin, for treatment of HGAIN. The light results in thermal coagulation to a controlled depth.

Infrared coagulation of HGAIN can lead to mild to moderate post-procedural pain and bleeding for up to two weeks. Complete healing usually occurs by two to four weeks. Rare complications (occurring <1% of the time) include infection of the treated area and severe bleeding resulting in emergency room evaluation or hospital admission. Severe bleeding can occur one to two weeks after the procedure.

There are no randomized clinical trial data to support the efficacy of IRC. The existing data are from retrospective reviews and one prospective single-arm clinical trial. One retrospective review of IRC in 68 HIV-positive men who have sex with men found that 72% of HGAIN lesions were successfully treated with a single IRC treatment. However, HGAIN lesions were commonly found in follow-up at other untreated sites resulting in approximately 60% having HGAIN after receiving one IRC treatment. Recurrent lesions were relatively common and had a similar response to a second treatment. A second study found a per-lesion cure rate of 64%.

A study of 18 HIV-positive participants found that 64% of these participants were cured of HGAIN lesions at one year. Ten of 18 participants had post-procedural pain described as mild to moderate. Eleven participants had post-procedural bleeding: 10 described the bleeding as mild and one participant described the bleeding as moderate.

Clinicians may also use cryotherapy (or freezing), trichloroacetic acid, or electrocautery to treat HGAIN. Several topical treatments, such as gels and creams, are under investigation, including 5-fluorouracil (a chemotherapy cream), imiquimod (a cream used to treat warts), and cidofovir (a drug used to treat cytomegalovirus infections).
Should HGAIN progress to anal cancer, the standard treatment is a combination of chemotherapy and radiation therapy, which is associated with significant morbidity. Many clinicians believe that anal cancer is a reasonable target for a cancer prevention strategy.

**Options for preventing HGAIN**

The HPV vaccination is a promising prevention tool that prevents against the 4 types of HPV that cause the majority of genital warts and cervical cancer. The Merck quadrivalent HPV vaccine was studied in a large clinical trial of young HIV-positive men and showed that the vaccine prevented genital warts in participants. The trial also included a substudy of young men who have sex with men and was shown to prevent anal infection of HPV in these participants.

The AIDS Malignancy Consortium presented data on the safety and immunogenicity of the quadrivalent vaccine in HIV-positive men. They found that the vaccine was safe and elicited a strong antibody response to each of the four HPV types.

The Merck quadrivalent HPV vaccine is FDA approved for prevention of cervical cancer in females age 9–26. The vaccine protects against two low-risk HPV types that cause 90% of warts and two high-risk HPV types that cause 70% of cervical cancers. Similarly, the FDA has approved this vaccine for males age 9–26 to prevent genital warts. The studies discussed above suggest that HPV vaccination in HIV-positive men and women will prevent anal HPV infections and associated anal cancer. However, most HIV-positive patients are older than 26 and have current or past HPV infections. It is not clear how much benefit the vaccine will yield in this population. HPV vaccination does not remove the need for cancer screening as anal cancer can be caused by HPV types not prevented by the vaccine.

Another prevention option to be considered is consistent use of condoms. Although condoms are not 100% effective in preventing new HPV infections, they have been shown to be partially effective. A randomized clinical trial of monogamous heterosexual couples with HPV infection found that couples that used condoms consistently had faster clearance of HPV infection and HPV-related lesions.

**Major Challenges in Implementing Anal Cancer Screening**

Accessing anoscopy and treatment for HGAIN. Over half of HIV-positive men who have sex with men and 20% to 30% of HIV-positive women will have abnormal anal cytology and require referral for anoscopy. It is preferable to perform anoscopy at a clinic that is prepared for a large number of clinical referrals. Unfortunately, these specialized clinics are not available in many places or the available clinics cannot accommodate the clinical need. Thus, many clinics and medical practices are developing the infrastructure to offer anoscopy within their clinics.

This procedure does not naturally fall under a single medical specialty. High-resolution anoscopy has been performed by general internists, infectious disease physicians, nurse practitioners, and physician assistants. Gynecologists, general or colorectal surgeons, gastroenterologists, and dermatologists also perform these procedures. Training usually begins with a course in cervical colposcopy by the American Society of Colposcopy and Cervical Pathology (ASCCP). The ASCCP also offers training in high-resolution anoscopy. It is helpful for medical practitioners to observe the procedure in clinical practice, and then perform the procedure with in-clinic supervision.

Lack of awareness regarding HPV and anal cancer. Many patients have little or no knowledge about HPV and anal cancer. It is important to help the patient understand the rationale for screening, existing gaps in knowledge, and the possible need for invasive procedures. Patients should make informed decisions before being screened for anal cancer.

Timothy Wilkin, MD, MPH, is an Associate Professor of Medicine at Weill Cornell Medical College.

*Portions of this article were previously featured in Medscape Today, on April 22, 2010.*
pipeline references


7 loftus, p. (2010, january 20) merck won’t seek fda approval for hiv drug. the wall street journal. retrieved from http://online.wsj.com/article/SB10001424052748254020057015051541.html


anal cancer references

1 bowmer, m., powles, t., newsum-davis, t. et al. hiv-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? j acquir immune defic syndr. 2004;37(5): 1563–1565.


5 pike, t., seeling-leneman, h., grabar, s. et al. marked increase in the incidence of invasive anal cancer among hiv-infected patients despite treatment with combination antiretroviral therapy. aids. 2008;22(10): 1203–1211.

6 silverberg, m., xu, l., chao, c. et al. immunodeficiency, hiv rna levels, and risk of non-aids-defining cancers. 17th conference on retroviruses and opportunistic infections, abstract 28.

7 silverberg, m. lau, d.’souza et al. trends in cumulative incidence of cancer among hiv-infected patients in north america 17th conference on retroviruses and opportunistic infections, abstract 758.

8 holly ea, raiston ml, darragh tm, greenblatt rm, ray, n. palefsky, j.m. prevalence and risk factors for anal squamous intraepithelial lesions in women. j natl cancer inst 2001;93(17): 843–9.


13 cranston rd, hirschowitz sl, cortina g, moe aa. a retrospective clinical study of the treatment of high-grade anal dysplasia by infrared coagulation in a population of hiv-positive men who have sex with men. int j std of aids 2008; 19: 118–20.

14 stier ea, goldstone se, berry j.m. infrared coagulator treatment of high-grade anal dysplasia in hiv infected individuals: an aids malignancy consortium pilot study. j aids 2008; 47: 56–61.


17 wilmke t, lee j, goldstone s, stier e, berry m, abouofia d, dorn d, einstein, m. mitsuyasu r, and palefsky j. safety and immunogenicity of the quadrivalent hpv vaccine in hiv-infected men: primary results of aids malignancy consortium trial 052. 17th conference on retroviruses and opportunistic infections 2010; abstract #1015.
